Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature
  1. Pubblicazioni

A phase 2 trial of rilzabrutinib in IgG4-related disease

Articolo
Data di Pubblicazione:
2026
Citazione:
A phase 2 trial of rilzabrutinib in IgG4-related disease / Stone, J.H., Carruthers, M., Baker, M.C., Meysami, A., Spiera, R., Ghetie, D., Valle, F.M., Dagna, L., Della-Torre, E., Schleinitz, N., Lally, L., Wu, T., Choi, J., Mikol, V., Yen, K., Mannent, L., Hagino, O.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - (2026). [10.1016/j.ard.2026.05.017]
Abstract:
Objectives: The objective of the article is to assess the efficacy and safety of rilzabrutinib, an oral, reversible inhibitor of Bruton’s tyrosine kinase, in participants with IgG4-related disease. Methods: This Phase 2a (NCT04520451) open-label, 52-week study enrolled 2 cohorts of participants with IgG4-related disease: Cohort A (participants who had failed or were intolerant to rituximab) and Cohort B (participants enrolled agnostic to rituximab history). Participants received rilzabrutinib plus a 2-to-4-week glucocorticoid (GC) taper followed by rilzabrutinib alone for up to 52 weeks. Primary endpoints were the proportion of participants without disease flare following first rilzabrutinib dose until the end of treatment and safety. Results: This study included 27 participants (Cohort A: 13; Cohort B: 14). At the end of treatment, 70.4% (19/27) of participants were flare-free and off GCs/immunosuppressants. Disease activity (mean [SD]), measured by IgG4-related disease Responder Index, decreased by 8.3 (5.8) at week 12 in both cohorts and by 10.7 (6.3) in participants who completed 52 weeks of rilzabrutinib (14/17). Serious treatment-emergent adverse events (TEAEs) occurred in 2 participants, 1 resulting in death, but both events were judged unrelated to the study drug. The most frequent TEAEs were diarrhoea, 40.7% (11/27); coronavirus disease 2019, 18.5% (5/27); and dizziness, 18.5% (5/27). Conclusions: Rilzabrutinib had an acceptable safety profile in patients with IgG4-related disease who had failed/ intolerant to rituximab and who were rituximab-naïve. Most participants discontinued GCs successfully without disease flares and exhibited sustained disease activity reduction. Further investigation of this potential alternative to B-cell–depleting therapies is needed in larger, long-term, placebo-controlled trials.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Stone, J. H.; Carruthers, M.; Baker, M. C.; Meysami, A.; Spiera, R.; Ghetie, D.; Valle, F. M.; Dagna, L.; Della-Torre, E.; Schleinitz, N.; Lally, L.; Wu, T.; Choi, J.; Mikol, V.; Yen, K.; Mannent, L.; Hagino, O.
Autori di Ateneo:
DAGNA LORENZO
DELLA TORRE EMANUEL
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/208956
Link al Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/208956/382955/PIIS0003496726002955.pdf
Pubblicato in:
ANNALS OF THE RHEUMATIC DISEASES
Journal
  • Dati Generali

Dati Generali

URL

https://ard.eular.org/article/S0003-4967(26)00295-5/fulltext
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.11.1.0